Social Responsibility

Myeloma New Zealand calls on Pharmac to make good on access deal

Health Industry Hub | January 15, 2020 |
[Total: 1    Average: 5/5]

Myeloma New Zealand is calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid) from April this year, allowing eligible patients access the subsidised drug earlier in their course of treatment.

As one of several groups that marched on Parliament in 2019 presenting petitions demanding an overhaul of New Zealand’s drug funding process and budget, Myeloma New Zealand are advocating for improved treatment access for the country’s second most common blood cancer. 

Dr Ken Romeril – consultant haematologist and founder of Myeloma New Zealand says “You often see a better response to novel treatments like lenalidomide when used up front, so we are calling on Pharmac to make good on their proposal and allow myeloma patients to access subsidised lenalidomide earlier in their treatment.

“The move will make a real difference to many Kiwis living with myeloma, especially those forced to fundraise to pay for the drug privately,” said Dr Romeril.

The deal is expected to help around 120 of the 400 New Zealanders diagnosed with myeloma each year. Myeloma is an incurable type of blood cancer that starts in the bone marrow and leads to serious complications such as kidney failure, bone pain and infections. 

Lenalidomide, which is currently funded for people whose disease has returned twice after initial treatments, would become available for some patients as a ‘maintenance’ treatment, taken orally early in the disease stage, but only after chemotherapy and a stem cell transplant. 

Enhance your business visibility, generate greater reach and differentiate your brand to Australia’s Pharma, MedTech, and Biotech industry professionals. Health Industry Hub is the only one-stop-hub connecting your business to all three industry sectors. Contact us to learn more about our unique media solutions.

In a separate move, Pharmac has also announced widened access to bortezomib, a myeloma treatment currently used for newly diagnosed myeloma patients. This deal removes restrictions allowing for longer and repeated treatment with bortezomib.

“Pharmac’s proposal to widen the use of lenalidomide and bortezomib would help improve access to drugs we’ve already been using for myeloma in New Zealand for some years” says Dr Romeril. 

“Myeloma follows a relapsing, remitting course and patients can have very individualised responses to treatments due to the complexities of the disease. There is still a substantially high unmet need for patients whose disease has progressed, with a number of very good novel treatments currently awaiting funding by Pharmac.

“We hope to see more good news soon, especially regarding drugs like daratumumab and carfilzomib. Although incurable, the innovations we’re seeing will mean we can treat this as a chronic illness instead of a terminal one,” says Dr Romeril.

Joy Wilkie, who has lived with myeloma for four years, is thrilled with the move to improve the management of myeloma in New Zealand, which is falling behind the rest of the world.

“Greater gains in quality of life and overall survival can be achieved with the availability of further myeloma treatment options. I’ve been in remission since 2016 and always look to see what Australia offers its myeloma patients. While the moves by Pharmac are a step in the right direction, we still have a way to go in New Zealand’s management of myeloma.”

However, not everyone is as pleased with the proposal saying the deal doesn’t go far enough, especially for those whose disease is longer standing. Patients who weren’t suitable for stem-cell transplant will also be ignored, as stem-cell transplant is a prerequisite to treatment access under the new proposal.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

“It’s a start, but what about the people who couldn’t have a transplant, had their transplant outside the time limit or whose disease has already relapsed?  We must see faster and better decisions when it comes to modern cancer medicines in New Zealand. The current system of rationing by delay is broken,” says Tania Crosbie, whose husband Paul was diagnosed with myeloma in 2014.

“I’m pleased to see clinicians given more freedom to utilise drugs like bortezomib and lenalidomide, this is progress, but they’re not new drugs. There remains a big gap for patients whose disease has relapsed, Pharmac has applications for three novel drugs that would go a long way towards helping these people.  When my husband relapses his next line of treatment is thalidomide.  I think New Zealand can do better than that,” says Mrs Crosbie.

You may also like Ovarian Cancer Australia calls for urgent action following the passing of two ambassadors


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Medical

Medical News - Paramedics Association concerned over uni students being thrown in to COVID-19 frontline

Paramedics Association concerned over uni students being thrown in to COVID-19 frontline

Health Industry Hub | April 1, 2020 |

The Australian Paramedics Association NSW (APA(NSW)) has significant concerns for the safety of patients, Paramedics and university students after NSW […]

More


News & Trends - Medical Technology

MedTech News - Australia's private hospitals join the COVID-19 fight in new partnership

Australia’s private hospitals join the COVID-19 fight in new partnership

Health Industry Hub | April 1, 2020 |

A new partnership with the Commonwealth Government will guarantee the viability of Australia’s private hospital sector, ensuring its full capacity […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche's adjuvant treatment PBS listed in early breast cancer

Roche’s adjuvant treatment PBS listed in early breast cancer

Health Industry Hub | April 1, 2020 |

Effective 1st April 2020, Roche’s Kadcyla is listed on the Pharmaceutical Benefits Scheme (PBS), for the adjuvant treatment of patients […]

More


Leadership & Management

Leadership & Management - Bill Gates's insights on COVID-19 global pandemic

Bill Gates’s insights on COVID-19 global pandemic

Health Industry Hub | April 1, 2020 |

In a recent TED Talk, philanthropist and Microsoft co-founder Bill Gates offers insights into the COVID-19 pandemic, discussing why testing […]

More